Implications of the LIFE trial

Sunil Nadar, Hoong Sern Lim, Gregory Y H Lip

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.

Original languageEnglish
Pages (from-to)871-877
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume12
Issue number5
DOIs
Publication statusPublished - May 1 2003

Fingerprint

Losartan
Left Ventricular Hypertrophy
Atenolol
Hypertension
Angiotensin Receptor Antagonists
Atrial Fibrillation
Electrocardiography
Blood Pressure
Morbidity
Mortality
Incidence

Keywords

  • Angiotensin receptor blockers
  • Cardiovascular mortality
  • Hypertension
  • Losartan

ASJC Scopus subject areas

  • Pharmacology

Cite this

Implications of the LIFE trial. / Nadar, Sunil; Lim, Hoong Sern; Lip, Gregory Y H.

In: Expert Opinion on Investigational Drugs, Vol. 12, No. 5, 01.05.2003, p. 871-877.

Research output: Contribution to journalReview article

Nadar, Sunil ; Lim, Hoong Sern ; Lip, Gregory Y H. / Implications of the LIFE trial. In: Expert Opinion on Investigational Drugs. 2003 ; Vol. 12, No. 5. pp. 871-877.
@article{7d931c35c4c846098c17cad2e7005aba,
title = "Implications of the LIFE trial",
abstract = "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.",
keywords = "Angiotensin receptor blockers, Cardiovascular mortality, Hypertension, Losartan",
author = "Sunil Nadar and Lim, {Hoong Sern} and Lip, {Gregory Y H}",
year = "2003",
month = "5",
day = "1",
doi = "10.1517/13543784.12.5.871",
language = "English",
volume = "12",
pages = "871--877",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Implications of the LIFE trial

AU - Nadar, Sunil

AU - Lim, Hoong Sern

AU - Lip, Gregory Y H

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.

AB - The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.

KW - Angiotensin receptor blockers

KW - Cardiovascular mortality

KW - Hypertension

KW - Losartan

UR - http://www.scopus.com/inward/record.url?scp=0038474043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038474043&partnerID=8YFLogxK

U2 - 10.1517/13543784.12.5.871

DO - 10.1517/13543784.12.5.871

M3 - Review article

C2 - 12720497

AN - SCOPUS:0038474043

VL - 12

SP - 871

EP - 877

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 5

ER -